Understand and agree! That makes the reward side of the equation even stronger.
In your opinion is there a annual cost where Iplex is not commercially viable? I assume that if the FDA approves that insurance companies must pay - how much latitude/authority do insurance companies have in these type of indications? (not trying to start an insurance company board debate) my sister's daughter has used close to $1million in health care cost for a rare condition and the insurance company has paid all of it.
On a side note, in their CC I wonder if Insmed is muzzled or being ultra conservative and staying away from any comments on the future use of Iplex for Short stature?
If I just made this deal I would play by the rules and if in doubt play very safe. No need to take unnecessary risk.
News 
Market Data 
Discover 
